Publication date
January 2014
DOIAbstract
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. [Blood. 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. [Blood. 2014
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristi...
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Increased absolute lymphocyte count (ALC) is a key feature of chronic lymphocytic leukemia (CLL) but...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
:Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemi
inhibits signaling and adhesion in response to CXCL12 and CXCL13 Th e phase 1 study of ibrutinib in...
There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisat...
In this issue of Blood, Byrd et al provide an important update on the prolonged ef ficacy and the li...
Chronic Lymphocytic Leukaemia (CLL) is associated with immune suppression and susceptibility to infe...
Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK). Studies published in the New Engl...
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED W...
The study by Ahn et al in this issue of Blood is an important clinical update with a 5-year follow-u...
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristi...
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Increased absolute lymphocyte count (ALC) is a key feature of chronic lymphocytic leukemia (CLL) but...
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refra...
:Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemi
inhibits signaling and adhesion in response to CXCL12 and CXCL13 Th e phase 1 study of ibrutinib in...
There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisat...
In this issue of Blood, Byrd et al provide an important update on the prolonged ef ficacy and the li...
Chronic Lymphocytic Leukaemia (CLL) is associated with immune suppression and susceptibility to infe...
Ibrutinib is a potent inhibitor of Bruton’s tyrosine kinase (BTK). Studies published in the New Engl...
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED W...
The study by Ahn et al in this issue of Blood is an important clinical update with a 5-year follow-u...
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic...
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexist...
Add to ORKG